Background. The putative genetic regulation of multidrug resistance gene-1 (MDR-1) gene expression and P-glycoprotein function has not yet been clearly delineated in patients with nephrotic syndrome (NS). We undertook this study to examine the distribution of three most frequent MDR-1 exonic polymorphisms G3435C, G2677T/A and C1236T in patients with NS and control children to investigate their usefulness as markers of responsiveness of the disease to steroids. Methods. Two hundred and sixteen children with NS and 216 healthy controls were genotyped for three exonic MDR-1 polymorphisms (G3435C, G2677T/A and C1236T) by using the polymerase chain reaction-restriction fragment length polymorphism technique. The frequency distribution of genotypes/alleles was compared between patients with NS and controls and also between steroid-sensitive NS (SSNS) and steroid-resistant NS (SRNS) patients. Results. Of the total 216 cases of NS (median age of onset 5 years, 165 males), 137 had SSNS, and 79 had SRNS. Homozygous mutants of C3435T (TT versus CC, P ¼ 0.034) and G2677T/A (TT 1 AA versus GG), P ¼ 0.030) were significantly higher in patients with NS compared to controls. The frequency distribution of homozygous mutant TT 1 AA compared to wild genotype GG was significantly higher in SRNS than SSNS patients (P ¼ 0.011) for G2677T/A, while the mutant genotypes for C3435T and C1236T were not different between SRNS and SSNS patients. The combination-bearing mutant genotype either of C3435T or G2677T/A exhibited a significantly higher frequency of mutant genotypes distribution in SRNS patients. MDR-1 haplotypes did not differ significantly between SSNS and SRNS patients. Conclusions. Patients with NS carrying homozygous mutants of single nucleotide polymorphism (SNP) G2677T/A are prone to develop SRNS. The synergistic effect of mutant genotypes of SNPs G2677T/A and C3435T in different combinations increase the risk of developing steroid resistance in patients with NS.
Introduction
Nephrotic syndrome (NS) is one of the most common primary glomerular diseases in children. Immune mechanisms, rather than primary structural defects of the filtration barrier, play a more prominent role in this clinical condition. Although all NS patients have similar biochemical alterations and clinical manifestations of the disease, substantial differences have been encountered in terms of a steroid responsiveness of the disease, steroid resistance and pattern of disease relapse. Approximately 60-80% of patients whose NS is responsive to glucocorticoid (GC) experience relapses of proteinuria, some of the cases remain steroid dependent and others become steroid resistant despite initial complete remission [1] . The reasons for the steroid resistance could be a change in the histopathologic pattern from a minimal-change disease to mesangial nephropathy or focal segmental glomerulosclerosis [2] , mutations of the gene encoding for the podocyte proteins nephrin, podocin, CD2AP and a-actinin-4 resulting in structural changes in the slit diaphragm [3] or factors that modulate the disease response to pharmacological interventions, such as the expression of P-glycoprotein (P-gp), a product of multidrug resistance gene-1 (MDR-1) gene [4] . Resistance to the therapeutic effects of GC due to increased P-gp expression has also been studied in patients with ulcerative colitis [5] , inflammatory bowel diseases [6] and rheumatoid arthritis [7] .
Oral GC treatment regimens may influence the natural history of NS [8] . Interindividual and intra-individual variability in response to exogenous GC may be partially due to differences in the activity of factors responsible for its systemic bioavailability, tissue distribution and elimination. It is becoming increasingly evident that genetic polymorphisms in the genes for membrane transporters (e.g. P-gp) and metabolizing enzymes may determine the outcome of drug therapies [9] . However, unresponsiveness of the disease to steroids could also occur independently of the expression of P-gp in NS patients.
P-gp is a glycosylated membrane protein that acts as an efflux pump and removes its substrates from inside the cell to outside. Some natural and synthetic GCs have been identified as the substrates of this efflux pump [10] . P-gp is also present in leukocyte membranes, where it protects against the accumulation of xenobiotics in the cytoplasm [11] . MDR-1 expression in lymphocytes has been reported to be negatively correlated with the response to prednisone, cyclophosphamide and cyclosporine A in children with NS [12] . Many studies have reported that certain single-nucleotide polymorphisms (SNPs) in the MDR-1 gene are associated with altered drug disposition [13, 14] . Anglicheau et al. [15] have shown that renal transplant recipients with homozygous mutations in G2677T/A required higher tacrolimus dose than recipients with no mutation, in order to receive the same therapeutic effect.
The putative genetic regulation of MDR-1 expression and P-gp function has not been clearly delineated in NS patients. Numerous genetic polymorphisms exist within the MDR-1 gene, and some are in strong linkage disequilibrium [16] . Novel indicators of the course of the disease have the potential to lead to improvements in the established therapeutic regimens. In the present case control study, we assess the distribution of the three most frequent exonic polymorphisms in MDR-1 gene G3435C, G2677T (A) and C1236T in NS patients and in age-and gendermatched healthy children to determine their usefulness as markers of resistance and responsiveness of the disease to steroids.
Materials and methods
All the children with NS who attended the nephrology clinic of Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, from January 2006 to March 2009 were included in the study. Healthy children from North India who were matched by age, gender and ethnicity were included in the study as controls. Children <1 year and >16 years and those with a family history of NS were excluded from the study. An Informed written consent was obtained from a parent or guardian of both patients and controls as per institute guidelines because all participants were <16 years. The study was approved by the ethics committee of the institute.
All NS cases fulfilled the International Study of Kidney Disease in Children criteria for the diagnosis of NS [17] . NS in children was defined as proteinuria of 40 mg/m 2 /h or ratio of 2 for spot urine protein (milligram)/creatinine (milligram) in the first morning urine sample with hypoalbuminemia (serum albumin <2.5 g/dL) and presence of edema. Remission of NS was defined by urinary protein excretion <4 mg/m 2 /h or urine dipstix nil/trace for three consecutive days. Relapse was defined as urinary protein excretion >40 mg/m 2 /h or urine dipstix11 or more for three consecutive days. Frequent relapses were defined as two or more relapses within 6 months of the initial treatment response or four or more relapses within any 12-month period. Steroid dependence was defined as two consecutive relapses occurring during the period of steroid taper or within 14 days of its cessation.
All of the participating children were treated with the standard initial therapy. This consisted of a daily dose of prednisolone 60 mg/m 2 body surface area for 6 weeks, then 40 mg/m 2 given on alternate days for 6 weeks and finally various steps of tapering on alternate days. Relapses were treated with daily prednisolone at 60 mg/m 2 until remission was achieved, followed by 40 mg/m 2 on alternate days. For steroid-dependent patients, a maintenance dose of prednisone was given on alternate days. The alternate dose was gradually tapered to determine the threshold at which each patient's relapse had occurred. Primary steroid resistance was defined as unresponsiveness of 60 mg/m 2 body surface area per day for 4 weeks of prednisolone therapy. Secondary steroid resistance was defined as no response to 4 weeks of daily prednisone therapy at a dose of 60 mg/m 2 /day in a child previously known to have a steroid-sensitive course. We excluded all steroid-resistant NS (SRNS) children with (i) underlying secondary causes, (ii) hepatitis B surface antigen seropositivity, anti hepatitis C virus seropositivity or human immunodeficiency virus seropositivity and (iii) with low serum complement (C3 and C4) levels.
The NS patients were categorized into two groups: (i) steroid-sensitive NS (SSNS) patients including those with infrequent relapses, or frequent relapses, and steroid dependency and (ii) SRNS patients included both primary and secondary steroid resistance.
Genotyping was performed in all NS patients and controls included in the study. The frequency distribution of wild and mutant genotypes and alleles of SNPs G3435C, G2677T (A) and C1236T were compared between patients with NS and controls and between patients with SRNS and SSNS. The synergistic effect of the inheritance of two to three SNPs among control, SSNS and SRNS was analyzed with zero (0) representing wild and heterozygous and 1 representing mutant genotype.
Genotyping
Blood for genotyping was drawn in the Ethylene Diamine Tetra Acetic Acid vials. DNA was extracted using a commercial kit (Qiagen) and stored at À20°C. To analyze polymorphic sites, we perform separate polymerase chain reaction (PCR) analyses followed by restriction fragment length polymorphism (PCR-RFLP) analysis. The primers, restriction enzymes and PCR conditions are shown in Table 1 . Random samples were reanalyzed in a double blind manner to confirm the RFLP results.
Statistical analysis
Student's t-test was used to compare the biochemical characteristics between patients with SSNS and SRNS. Shapiro-Wilks test was used to determine the parametric or nonparametric distribution of data. Student's t-test was used to compare the parametric variable and Mann-Whitney Utest was used for the comparison of nonparametric variables. Chi-square (v2) test was used to compare the frequency distribution of genotypes and alleles between patients with NS and control population and also between patients with SSNS and SRNS. The synergistic effect of homozygous mutant genotype compared to wild type or heterozygous mutant genotypes in varying combinations among control, SSNS and SRNS patients was analyzed by using chi-square test. A P-value of <0.05 was considered significant. Statistica version 6.0 was used for the data analysis. Estimation of haplotype frequency was done by Haploview software [18] .
Results

Demographic and biochemical profiles
Two hundred and sixteen NS children (boys 165, median age of onset 5 years, range 1-16 years) and 216 age-and gender-matched healthy children (boys 155, median age 6 years, range 1-16 years) were included in the study. Of the children with NS, 137 (63.4%) had SSNS and 79 (36.6%) patients had SRNS. The mean age of onset was higher for SRNS (9.18 AE 6.7 years) than for SSNS (5.69 AE 4.58 years) (P < 0.01) patients. The biochemical profiles and estimated glomerular filtration rate (GFR) of patients with SSNS and patients with SRNS are summarized in Table 2 . The GFR was estimated by using Schwartz equation and constant as mentioned in a former study [19] . The mean level of serum creatinine was significantly higher in patients with SRNS than patients with SSNS. The serum protein level and ratio of spot urine protein to creatinine were higher in patients with SSNS than in patients with SRNS. The mean levels of hemoglobin, blood urea nitrogen and serum albumin between SSNS and SRNS patients were similar between SSNS and SRNS patients. Of the 79 SRNS patients, 41(51.9%) had focal segmental glomerulosclerosis, 34 (43%) had minimal-change disease and 4 (5.1%) were not biopsied because the parents had not given consent for kidney biopsy. 
MDR-1 SNPs genotypes and alleles in patients versus control
In terms of SNP C1236T, there were no significant differences in frequency distribution of the genotypes or alleles between the patient with NS and control children.
MDR-1 SNPs genotypes and alleles in patients with SSNS versus patients with SRNS
The frequency distribution of the G2677T/A gene, homozygous mutant genotype TT 1 AA compared to the wild genotype GG was significantly higher in SRNS compared to SSNS patients (v 2 ¼ 6.53, P ¼ 0.011) ( Table 4) . However, the frequency distribution of mutant allele T 1 A compared to wild allele G was not significantly different between SRNS and SSNS patients (v 2 ¼ 3.12, P ¼ 0.077). In terms of the C3435T and C1236T SNPs, there were no differences in the frequency distribution of genotypes and alleles between patients with SSNS and patients with SRNS (Table 4) .
Synergistic effect of two or three MDR-1 SNPs genotype
When synergistic effect of two or three SNPs in different combinations was evaluated together among SSNS, SRNS and control groups with zero (0) representing wild and heterozygous and 1 representing mutant genotype (Table 5) , it was observed that the combination bearing mutant genotype either of C3435T or G2677T/A exhibited a significantly higher frequency of genotype distribution in steroid-resistant patients.
MDR-1 SNPs genotypes and alleles with respect to age <6 years versus !6 years On analysis, the frequency distribution of genotypes and alleles of three MDR-1 SNPs (C3435T, C1236T and G2677T/A) with respect to age of onset <6 years versus !6 years (Table 6 ), C3435T exhibited significantly higher homozygous mutant TT compared to wild CC in age <6 years compared to !6 years (TT versus CC: v 2 ¼ 4.34, P ¼ 0.037; CT 1 TT versus CC: v 2 ¼ 4.04, P ¼ 0.045). Whereas the alleles (T versus C) did not show a significant difference (v 2 ¼ 3.48, P ¼ 0.062) between the two age groups. The frequency distribution of different genotype and alleles of MDR-1 gene G2677T/A and C1236T did not show any significant difference between the two age groups (Table 6 ). 
Haplotype analysis
Haplotype analysis revealed that the frequency distribution of MDR-1 haplotypes did not differ significantly between patients with SSNS and patients with SRNS. However, it differed significantly with respect to age of onset. The haplotype CGC (for SNPs C3435T, G2677T/A and C1236T, respectively) was significantly more common in patients with age of onset !6 years than among patients with an age of onset <6 years (Table 7) .
Discussion
In this study, frequency distribution of homozygous mutant genotypes of SNPs G2677T/A and C 3435T were significantly higher in children with NS compared to healthy children. The frequency distribution of mutant genotype of C2677T/A was significantly higher in patients with SRNS than the patients with SSNS. Moreover, the presence of homozygous mutant genotypes of both 
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G2677T/A and C3435T in different combinations pose a higher risk of developing resistance to steroids in patients with NS compared to the wild and heterozygous mutants of these genes.
The higher frequency of the C3435T polymorphism in patients with NS compared to control children indicated that it may be a marker for susceptibility to developing NS. The exact role of the MDR-1 gene in the When first reported, this SNP C3435T was associated with variations in intestinal expression and function of P-gp, and the area under curve for orally administered digoxin was larger for the 3435T/T allele than for the 3435C/C allele [20] . Several groups have reported that this SNP is associated with decreased MDR-1 expression in CD561 natural killer cells [21] and placental tissues [22] . Von Ahsen et al. [23] found no association between this SNP and the dose and efficacy of cyclosporine. Other reports have led to contradictory reports, Kim et al. [24] reported a decrease in fexophenadine with the T allele of this SNP. The prevalence of the C allele has been reported to be 49% and T allele to be 51% in Indian subjects which is lower compared to African populations but similar to other Caucasian and Asian populations [18, 25] . The homozygous mutant genotype of SNP C3435T alone was not associated with the steroid-resistant phenotype in this study. However, when it was combined with the mutant C1236T and 2677T/A, it was associated with the steroid resistant phenotype. The association and discrepancies described suggest that it may be in linkage disequilibrium with other functional polymorphisms. It was also observed that the frequency distribution of the homozygous mutant genotype of G2677T/A gene is much higher in patients with NS compared to controls and also higher in patients with SRNS compared to patients with SSNS. G2677T/A polymorphisms are located in Exon 21, on the intracellular side of MDR-1 gene. With this SNP, the alanine at position 2677 is replaced by serine or threonine, which results in a change from a lipophilic residue to a hydrophilic one. Because alanine is a structurally neutral amino acid, it is possible that substitution of serine or threonine would affect the geometric precision of the interaction site and secondary structure [24] . This may have led to increased efficiency of the mutated protein which was able to efflux out GC or its active metabolites resulting in steroid resistance. In a recent study on renal transplant recipients, the tacrolimus dose requirement was 40% higher for the same therapeutic effect in homozygous mutant than wild-type patients for this SNP G2677T/A [15] . Among Indians, G allele frequency is higher than the German and Japanese populations [24, 25] . From this data, it is speculated that NS patients who carry the T/A would be more resistant to steroids and would be more susceptible for developing SRNS. The TT 1 AA genotype probably does contribute to the P-gp-mediated drug-resistant phenotype by either increased expression of P-gp or increased functionality of P-gp.
C1236T is located in Exon 12, in one of the intracellular loops of the protein adjacent to the Adenosine Tri-Phosphatebinding/utilization domain. C1236T is a synonymous variant that does not result in any change in the protein sequence. However, it may affect translation regulation, RNA stability or other molecular mechanisms. It may also have an indirect effect being linked to a causal variant. The allele frequencies of C1236T differ between various populations with major differences among Caucasians, Asians and Africans [20, 24, 26, 27] . In a recent study, it has been shown that TT genotypes minimize P-gp activity in a substrate-dependent manner [28] . In our study, the genotype and allele frequencies were similar to those reported for a Polish population [4] . However, C1236T polymorphisms did not have any significant impact on steroid resistance in our patient population.
Haplotype analysis of patients with SSNS and patients with SRNS revealed that the distribution of MDR-1 haplotypes did not differ significantly between these groups, while it differed significantly among patients with respect to age of onset. The frequency of haplotype CGC for C3435T, G2677T/A and C1236T in patient with age of onset !6 years was found to be significantly higher as compared to patients with age of onset <6 years. Haplotypic analysis did not reveal much information.
Overall, our results demonstrated that different genotypes of C1236T, C3435T and G2677T/A restriction sites alone or in different combinations are associated with steroid resistance in NS, suggesting that these genotypes may be associated with some factors which participate in the causation of steroid resistance. The pharmacokinetic evaluation of several genes implicated in drug pharmacokinetics has provided efficient tools for individualizing drug therapy by optimizing drug dosage. This would both improve drug efficacy and prevent adverse effects, particularly drugs like steroids with multiple toxicities.
However, we have not studied the mutation in the genes coding for the podocyte proteins that may have contributed to the SRNS phenotype and we have excluded patients with family history of NS. We have also not studied the functional efflux assays and P-gp expression on the peripheral blood mononuclear cells, which could have provided a better understating between the MDR polymorphisms and drug resistant phenotype. The hypothesis also needs to be confirmed by in vitro experiments.
To conclude, our patients from northern India showed that NS patients carrying homozygous mutations in G2677T/A are more prone to developing steroid resistance. 
